Image de couverture de livre

Cardiovascular phenotypes in type 2 diabetes: Latent class analysis of the CANVAS Program and CREDENCE trial

Fuente: Wiley Open Access

Enregistré dans:

Détails bibliographiques
Auteurs principaux:	Amir Razaghizad, Jiayi Ni, Pedro Marques, Thomas A. Mavrakanas, Michael A. Tsoukas, Elite Possik, Thao Huynh, Jodi D. Edwards, Peter Liu, Walter Swardfager, Frederic Baroz, João Pedro Ferreira, Abhinav Sharma
Format:	Artículo Open Access
Publié:	Wiley 2024
Sujets:	Diabetes, Obesity and Metabolism
Accès en ligne:	Acceder al recurso
Tags:	Ajouter un tag Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires

The Effect of Canagliflozin Dose on Renal and Cardiovascular Outcomes in Type 2 Diabetes and High Cardiovascular Risk
par: Elias John Elenjickal, et autres
Publié: (2026)

Utilizing synchronous care to improve cardiovascular and renal health among patients with type 2 diabetes: Proof‐of‐concept results from the DECIDE ‐ CV clinical programme
par: Pedro Marques, et autres
Publié: (2024)

Machine learning for prediction of chronic kidney disease progression: Validation of the Klinrisk model in the CANVAS Program and CREDENCE trial
par: Navdeep Tangri, et autres
Publié: (2024)

An overview of the CANVAS Program and CREDENCE trial: The primary outcomes and key clinical implications for those managing patients with type 2 diabetes
par: Angela X. Chen, et autres
Publié: (2024)

Geographic and racial variability in kidney, cardiovascular and safety outcomes with canagliflozin: A secondary analysis of the CREDENCE randomized trial
par: Kathryn Cardoza, et autres
Publié: (2024)

Semaglutide withdrawal in adults with type 1 diabetes on pump therapy: A post‐hoc analysis from a double‐blinded randomized controlled trial
par: Melissa‐Rosina Pasqua, et autres
Publié: (2025)

Changes to insulin requirements over time with semaglutide in adults with type 1 diabetes on insulin pump therapy: A post‐hoc analysis of a double‐blinded, randomised, crossover trial
par: Melissa‐Rosina Pasqua, et autres
Publié: (2025)

Variability in HbA1c and the risk of major clinical outcomes in type 2 diabetes with chronic kidney disease: Post hoc analysis from the CREDENCE trial
par: Ying Zhu, et autres
Publié: (2025)

Prediction of new‐onset heart failure in patients with type 2 diabetes derived from ALTITUDE and CANVAS
par: Fatema Said, et autres
Publié: (2024)

Characterization of the effect of naltrexone/bupropion on body composition
par: Vanessa Tardio, et autres
Publié: (2025)

Semaglutide and cardiovascular risk in type 1 diabetes: A predictive modelling analysis in a double‐blind, randomised, placebo‐controlled cross‐over trial
par: Luxcia Kugathasan, et autres
Publié: (2026)

Association of type III collagen turnover with cardiovascular outcomes and impact with canagliflozin in the CANVAS Program: A post hoc analysis
par: Daniel G. K. Rasmussen, et autres
Publié: (2024)

Effects of SGLT2 inhibitors across the spectrum of albuminuria in cardiovascular–kidney–metabolic conditions: A pooled analysis of randomised trials
par: João Pedro Ferreira, et autres
Publié: (2025)

Cardiovascular and kidney outcomes of GLP ‐1 receptor agonists in adults with obesity: A target trial emulation study
par: Huilin Tang, et autres
Publié: (2025)

Cardiovascular outcomes under hypothetical blood‐pressure‐lowering intervention in type 2 diabetes: A target trial emulation
par: Xue Tian, et autres
Publié: (2026)

The latest evidence and clinical guidelines for use of meal replacements in very‐low‐calorie diets or low‐calorie diets for the treatment of obesity
par: Shenelle A. Edwards‐Hampton, et autres
Publié: (2024)

A systematic review of glucocorticoid use in type 1 diabetes: Glycaemic effects and clinical management strategies
par: Alexandra Katz, et autres
Publié: (2026)

Effects of Dapagliflozin on Cardiovascular Outcomes in Patients With Type 2 Diabetes at Risk of Liver Fibrosis
par: Jan Oscarsson, et autres
Publié: (2026)

Proteomic Profiling Captures Residual Cardiovascular Risk Beyond the PREVENT Model in Individuals With Cardiovascular–Kidney–Metabolic Syndrome Stages 2–3
par: Xuefei Han, et autres
Publié: (2026)

GIP in Cardiovascular and Kidney Disease: From Physiology to Pharmacology
par: Michelantonio De Fano, et autres
Publié: (2026)

Hyperaldosteronism in the Pathophysiology and Management of Cardiovascular‐Kidney‐Metabolic Syndrome
par: Evan Zeitler, et autres
Publié: (2026)

Cardiovascular risk reduction with glucagon‐like peptide‐1 receptor agonists is proportional to HbA1c lowering in type 2 diabetes: An updated meta‐regression analysis incorporating FLOW and SOUL trials
par: Masashi Hasebe, et autres
Publié: (2025)

Semaglutide and Cardiovascular Outcomes According to Baseline Aspirin Use: Analyses of the SOUL and SELECT Trials
par: Dirk Müller‐Wieland, et autres
Publié: (2026)

Comparative Predictive Value of Three Visceral Adiposity Indices for Cardiovascular Disease: A 17.5‐Year Korean Cohort Study
par: A‐Ra Cho, et autres
Publié: (2026)

Cardiovascular Disease Risk Prediction in Patients With Metabolic Dysfunction‐Associated Steatohepatitis
par: Joe Hollinghurst, et autres
Publié: (2026)

Prevalence of Albuminuria Across Cardiovascular‐Kidney‐Metabolic Phenotypes in the United States
par: Sophie E. Claudel, et autres
Publié: (2026)

Cardiovascular and non‐renal complications of chronic kidney disease: Managing risk
par: Peter Rossing, et autres
Publié: (2024)

Lower Risk of Cardiovascular Events in Patients With Clinical Atherosclerotic Cardiovascular Disease Who Initiated Semaglutide 2.4 mg in the Real‐World: Results From the SCORE—Clinical ASCVD Study
par: Michael G. Nanna, et autres
Publié: (2026)

Impact of Simulated Risk Factor Management on Cardiovascular Disease and Costs in Type 2 Diabetes Using the ABC Model
par: Lee‐Ling Lim, et autres
Publié: (2026)

Comparative effectiveness of continuous positive airway pressure and glucagon‐like peptide‐1 receptor agonists in obstructive sleep apnea: A network meta‐analysis of randomised trials
par: Gaspar R. Chiappa, et autres
Publié: (2026)

Predictors of diabetic ketoacidosis in patients with insulin‐deficient diabetes phenotype initiating SGLT2 inhibitors
par: Anat Tsur, et autres
Publié: (2025)

Assessing the benefit–risk profile of newer glucose‐lowering drugs: A systematic review and network meta‐analysis of randomized outcome trials
par: Huilin Tang, et autres
Publié: (2024)

Comparative efficacy and tolerability of currently approved incretin mimetics: A systematic analysis of placebo‐controlled clinical trials
par: Yu Mi Kang, et autres
Publié: (2025)

Comment on ‘Semaglutide and Tirzepatide Effects on Cardiovascular Outcomes in People With Overweight or Obesity in the Real World ( STEER )’
par: Chih‐Yuan Wang
Publié: (2026)

Real‐World Cardiovascular Outcomes of Obesity Treatment With Tirzepatide Versus Semaglutide in Non‐Diabetic Adults
par: Mai Katsura, et autres
Publié: (2026)

Association of Cardiovascular‐Kidney‐Syndrome and Brain Macrostructure and Microstructure Injury: A Prospective Cohort Study
par: Guanyu Niu, et autres
Publié: (2026)

Dietary Fibre, Gut Microbiota and Cardiovascular Outcomes: Differential Associations by Diabetes Status in Multiethnic Cohorts
par: Yuwei Li, et autres
Publié: (2026)

Modification of the association between obesity phenotypes and cardiovascular disease by social determinants of health: A prospective cohort study
par: Qiujin Huang, et autres
Publié: (2026)

Kidney outcomes with SGLT2 inhibitors in patients with diabetes and an insulin‐deficient phenotype: A real world analysis
par: Anat Tsur, et autres
Publié: (2025)

Association of KLF14 rs4731702 gene polymorphism with metabolic phenotype in young patients with type 1 diabetes
par: Monika Ryba‐Stanisławowska, et autres
Publié: (2024)